相关临床试验
16
9 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
进行中（未招募）
4
25.0%
已完成
3
18.8%
Enrolling By Invitation
1
6.3%
尚未招募
4
25.0%
招募中
1
6.3%
终止
2
12.5%
撤回
1
6.3%
暂无批准数据
- New research from Target RWE presented at EASL 2025 demonstrates that individuals with Type 2 diabetes have significantly higher risk of progressing from MASH to cirrhosis, independent of age, sex, or fibrosis risk group. - The findings, co-authored by Dr. Michael Roden from Target RWE's MASH steering committee, emphasize the urgent need for early MASH detection in diabetic patients as MASLD prevalence continues to rise globally. - Target RWE has reached a milestone of over 600,000 patients enrolled in its TARGET-Liver Disease observational study, conducted in partnership with the American Association for the Study of Liver Diseases.
• Target RWE presented significant findings on MASH and HCC at EASL Congress 2025, revealing that Type 2 diabetes substantially increases the risk of progression to MASH-related cirrhosis. • The company's Chief Medical Officer participated in the PBC Consensus Conference, focusing on developing surrogate endpoints and integrating real-world evidence into clinical trials for Primary Biliary Cholangitis. • With over 600,000 patients enrolled in its TARGET-Liver Disease observational study, Target RWE continues to advance understanding of chronic liver diseases through its partnership with the American Association for the Study of Liver Diseases.
